Paratek begins rolling NDA of omadacycline for ABSSSIs and CABP

Paratek Pharmaceuticals Inc. (NASDAQ:PRTK) began submission of a rolling NDA to FDA for omadacycline (ZL-2401) to treat acute bacterial skin and skin structure infections (ABSSSIs) and community-acquired bacterial pneumonia (CABP). The company expects to complete the submission this quarter...